Facebook
Twitter
LinkedIn
Forward
Targeting DED: Real-World Strategies From the Frontlines of Eye Care (CE Symposium)
To claim your credit for the symposium, please click Register/Take Course.
Thursday, March 14, 2024
6:00 PM – 6:30 PM ET Registration and Dinner
6:30 PM – 8:30 PM ET CE Symposium and Virtual Broadcast
Pendry Manhattan West
Ballroom, 5th Floor
438 West 33rd Street
New York, New York
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Incorporate diagnostic strategies for DED into practice
- Review the pathophysiologic factors of DED
- Design evidence-based treatment plans for patients with DED
Faculty
 | Paul Karpecki, OD, FAAO (Chair) |
 | Mile Brujic, OD, FAAO Partner Premier Vision Group Bowling Green, Ohio |
 | Walter O. Whitley, OD, MBA, FAAO Director, Optometric Services Virginia Eye Consultants Virginia Beach, Virginia |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.
Faculty
Mile Brujic, OD, is a consultant for AbbVie Inc, Aldeyra Therapeutics*, Apellis Pharmaceuticals, Avellino*, Bausch & Lomb Incorporated, Glaukos Corporation, Lentechs*, Novartis Pharmaceuticals Corporation*, Radius XR, LLC, RVL Pharmaceuticals, Inc*, Santen Inc*, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Viatris Inc, Visus Therapeutics, Visionix, and ZeaVision LLC; is a contracted researcher for ABB Optical Group, Amgen Inc, Art Optical Contact Lens, Inc, Contamac, Dompé US, Inc, Johnson & Johnson Vision Care, Inc, MDelite Laser & Aesthetic, Notal Vision, Tangible Science, and Walman Optical; and is on the speakers bureau for Bausch & Lomb Incorporated, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and Viatris Inc.
Paul Karpecki, OD, is a consultant for AbbVie Inc, AdOM Optical Technologies Ltd, Alcon, Aldeyra Therapeutics, Ametek, Inc*, Amgen Inc, Apellis Pharmaceuticals, Astellas Pharma Inc, Atlas Medical GmbH, Aurion Biotechnologies, Avellino, Azura Ophthalmics, Bausch & Lomb Incorporated, Bio-Tissue, BlephEx*, Bruder Healthcare, Bruno Vision, Cambium Medical Technologies*, Dompé US, Inc, Eyedetec Medical, Eyesafe Inc, Gobiquity*, Haag-Streit Group*, Harrow, Inc, Hilco Vision*, iCare USA Inc, Kala Pharmaceuticals*, Keplr Vision*, Kiora Pharmaceuticals, Inc*, Konan Medical USA, Inc, Lentechs, MacuLogix, Inc*, Neurolens, Nordic Pharma, Novartis Pharmaceuticals Corporation, OASIS Medical, OCULUS, Inc, OcuMedic, Inc, Ocuphire Pharma, OCuSOFT Inc, Olympic Ophthalmics Inc, Orasis Pharmaceuticals, Oyster Point Pharma, Inc*, Regener-Eyes, Reichert, Inc, Rendia, Inc, RVL Pharmaceuticals, Inc, RxSIGHT, Topcon Medical Systems, Inc, ScienceBased Health, Scope, Sentiss Pharma Pvt Ltd, Sight Sciences, SilkTech Biopharmaceuticals, StepWise Medical*, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Sydnexis Inc, Tarsus Pharmaceuticals, Inc, TearClear, Thea Pharmaceuticals Limited, Vial, Viatris Inc, Vital Tears LLC, and Zeiss; is an advisory board member of AstaReal, Inc*; and is on the speakers bureau for Aerie Pharmaceuticals, Inc*, Bausch & Lomb Incorporated, Dompé US, Inc, Johnson & Johnson Vision Care, Inc*, Mallinckrodt, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and Viatris Inc.
Walter O. Whitley, OD, MBA, is a consultant for AbbVie Inc, Alcon, Aldeyra Therapeutics, Apellis Pharmaceuticals, Astellas Pharma Inc, Bruder Healthcare, Dompé US, Inc, Eyenovia, Inc, Heru, Inc, Mediprint, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, Regener-Eyes, Tarsus Pharmaceuticals, Inc, and Thea Pharmaceuticals Limited; is an advisory board member of AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Bruder Healthcare, Oyster Point Pharma, Inc, ScienceBased Health, Tarsus Pharmaceuticals, Inc, and Visus Therapeutics; is on the speakers bureau for AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; and is a contracted researcher for Heru, Inc.
Planners, Managers, and Writers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
* The financial relationship existed during the past 24 months but has now ended
Accreditation Statement
COPE approved for 2.0 CE credits for optometrists.
COPE Course ID: 90340-TD (Synchronous In Person)
COPE Course Category: Treatment/Management of Ocular Disease
Administrator: 
This activity, COPE Activity Number 128016, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.
The content of this COPE-Accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Bausch & Lomb Incorporated.
This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 319.1
Available Credit
- 2.00 COPE